Therapeutic potential of protein and adjuvant vaccinations on tumour growth

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2583-2589

  Gerard C M ^a   Baudson, N ^a   Kraemer, K ^b   Bruck, C ^a   Garcon N ^a   Paterson, Y ^c   Pan, Z K ^c   Pardoll, D ^b  

^a SmithKline Beecham Biologicals   (Belgium)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvants; Cancer immunotherapy; HPV E7 protein

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULANT MPL; IMMUNOSTIMULATING AGENT; PROTEIN E7; QS 21; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG FORMULATION; IMMUNOSTIMULATION; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODIES, VIRAL; CANCER VACCINES; FEMALE; IMMUNOGLOBULIN G; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, NUDE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0035925670     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00486-2     Document Type: Conference Paper

References (23)

1. Ubiquitous nature of E6 and E7 in tumours?
2. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
3. Continued expression of HPV 16 E7 protein is required for maintenance of the transformed phenotype of cells cotransformed by HPV-16 plus EJ-ras
4. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
5. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
6. Characterization of the anti-tumor immune response in humans cancers and strategies for immunotherapy
7. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III
8. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
9. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma
10. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding
11. MPL formulations for the next generation of vaccines
12. Advances in vaccine adjuvants
13. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
14. Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia
15. Experimental vaccine strategies for cancer immunotherapy
16. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses
17. Immunomodulation by iscoms, immune stimulating complexes
18. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1
19. Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants
20. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL
21. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
22. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
23. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group